Loading
MoonLake Immunotherapeutics Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Oct 2025.
MoonLake Immunotherapeutics: what insiders have been doing
MoonLake Immunotherapeutics is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 28 filings were filed, from 6 insiders.
The flow runs one way only: 21 sales worth €65.6M, from 4 insiders, and no purchase. The totals do not cover 3 filings with an undisclosed amount. The largest single trade was a sale of €28.0M by BVF Partners L P/il, published on 2 April 2026.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Compared with its exchange (5,811 companies, median 19 filings), a count of 28 filings is above the norm. Over the whole record (from 2022), the tally stands at 6 purchases and 33 sales.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
59
Thresholds
n/a
Buy Volume
€52M
6 ops. · all time
Sell Volume
€177M
33 ops. · all time
Who traded when
BuySaleMatthias Bodenstedt1 buy7 sales
Kristian Reich6 sales
da Silva Jorge Santos5 sales
BVF Partners L P/il3 sales
Chen Bihua1 sale
Since the insiders bought
- +39.8%Entry US$10.26 · Close at T+90 US$14.34
- -14.4%Entry US$54.88 · Close at T+365 US$47.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MoonLake Immunotherapeutics Buy (bullish), based on 13 analysts. Average price target: US$28.54.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$10.26
Analyst consensus
13 analystsBuy
US$6.00Target US$28.54(+178%)US$50.00
Income statement
EBITDA-US$219.8M
Net income-US$227.3M0.0% margin
Valuation
PER (forward)-3.1x
P/Book2.0x
Beta1.08
Balance sheet & cash
Market capUS$873.2M
Total debtUS$75.7M
Free Cash Flow-US$196M
Debt / Equity24%
Profitability & ownership
ROE-67.5%
ROA-32.4%
% insiders8.2%
% institutions87.9%
Last declaration on 29 July 2026
Declarations59 total
1,100 shares@ US$20.000.0021% mcap0.2% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-082804:0
50,000 shares@ US$20.020.097% mcap7.8% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-080869:0
2,448 shares@ US$20.000.0047% mcap0.4% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-080869:1
43,700 shares@ US$20.090.085% mcap6.8% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-080133:0
16,105 shares@ US$20.010.031% mcap2.5% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-079376:0
150,000 shares@ US$19.440.28% mcap22.6% of flowClass A OrdinarySEC144:0001969223-26-000787
33,936 shares@ US$20.010.066% mcap4.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-077564:0
68,289 shares@ US$20.020.13% mcap9.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-077564:1
150,000 shares@ US$20.030.29% mcap20.5% of flowClass A OrdinarySEC144:0001969223-26-000744
39,120 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-071075:0
15,082 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:0
2,794 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-070259:1
150,000 shares@ US$19.000.16% mcap21.8% of flowClass A OrdinarySEC144:0001969223-26-000703
13,653 shares@ US$20.020.019% mcap3.4% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-055799:0
2,426 shares@ US$19.560.0029% mcap0.6% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-044642:0
51,873 shares@ US$18.230.058% mcap6.3% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-043647:1
98,127 shares@ US$18.410.11% mcap12.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-043647:0
85,870 shares@ US$18.9420.1% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-042629:0
1,925 shares@ US$19.510.0023% mcap0.5% of flowClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-042629:1
1,932,354 shares@ US$16.7919.3% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-26-000895:0
1,569,116 shares@ US$16.7915.7% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-26-000895:1
248,530 shares@ US$16.792.5% of flowClass A Ordinary Shares, $0.0001 par valueSEC:0000921895-26-000895:2
354,296 shares0Class A ordinary shares, par value $0.0001 per shareSEC:0001213900-26-002907:0
294,473 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-124519:0
35,389 sharesClass A ordinary shares, par value $0.0001 per shareSEC:0001213900-25-124516:0
25 of 59 declarations
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biotechnology company based in the United States and listed on the NASDAQ market. Founded in 2021 by an international team of immunology specialists, the company has built its strategy around a single lead asset, sonelokimab (SLK), a tri-specific Nanobody® designed to target the IL-17A/IL-17F inflammatory pathway. While MoonLake’s operational headquarters are in Zug, Switzerland, it is still a U.S.-listed issuer that is closely followed by investors in growth healthcare and biotech.
MoonLake’s business model is that of a development-stage company: it does not yet commercialize a product and instead focuses on clinical development, regulatory planning, and manufacturing readiness. The investment case is centered on SLK’s potential to become a differentiated therapy across inflammatory diseases with substantial unmet need, especially hidradenitis suppurativa (HS), palmoplantar pustulosis (PPP), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Management describes the strategy as a “pipeline within a product,” meaning one molecule being advanced across multiple related indications.
Read moreShow less
From a competitive standpoint, MoonLake operates in therapeutic areas where biologic treatments already exist, but where response depth, durability, tolerability, and convenience remain key differentiators. The company positions SLK as an IL-17A/F-balanced inhibitor with the potential for deep tissue penetration and strong clinical activity in both skin and joint disease. That places MoonLake in direct competition with much larger dermatology and rheumatology franchises, but with a narrow, highly focused scientific profile that could create upside if clinical execution remains strong.
Recent news has materially advanced the regulatory narrative. In January 2026, MoonLake said it received positive FDA feedback on its biologics license application strategy for HS, supporting a planned BLA submission in the second half of 2026. In February 2026, the FDA granted Fast Track designation to sonelokimab in PPP, improving the development pathway for that program. The company also released updated clinical data through 2025 and early 2026 across the VELA, MIRA, LEDA, S-OLARIS and IZAR programs, creating a busy catalyst calendar. For international investors, MoonLake remains a high-risk, high-upside biotech story driven by a single lead asset, rapid clinical execution, and a heavy dependence on future regulatory milestones.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
